Merck & Co said it sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
The therapy is the first in more than seven years to show a significant extension in overall survival in metastatic non-small cell lung cancer (NSCLC) in late-stage study.
Traditional pharmaceutical sales and marketing approaches will be inefficient when trying to reach such a small population. To maximize efficiency and effectiveness of commercial efforts, commercial leaders must take a creative approach to their targeting strategy.
San Diego-based Illumina is arguing that the FTC “violated due process by depriving Illumina and Grail of a fair proceeding before an impartial tribunal,” according to the filing in the U.S. Fifth Circuit Court of Appeals.
The company made the announcement this morning.
A panel of outside advisers to the U.S. Food and Drug Administration is scheduled to meet on June 15 to discuss strain selection for this year’s COVID-19 booster shots, and regulators are expected to make their decision shortly afterward.
The drug, efruxifermin, also met secondary efficacy goals when tested alongside a diabetes treatment belonging to a class of drugs known as GLP-1 receptor agonists in the trial.
Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.
The recent FDA approval of Biogen’s Qalsody for superoxide dismutase 1 (SOD1)–ALS highlighted the potential for antisense oligonucleotides in central nervous system diseases. But the recent failure of Wave Life Sciences’ WVE-004 in C9orf72–ALS also showed their limitations.
